NCT Number: NCT00975455
Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer
The purpose of the study is to evaluate subjects with gross or microscopic hematuria undergoing scheduled cystoscopy to determine the absence or presence of bladder cancer.
Looking for future studies?
Notify MeKey information
Conditions
Age range
45 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Atlantic Urological Associates, Daytona Beach, Florida, United States
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- For those subjects for whom there is no family history of bladder cancer or less than a 20 pack year history of cigarette smoking, subject must be 50 or older.
- Subject's age can be lowered to 45 or older if there is a family history of bladder cancer and/or a 20 or greater pack history of cigarette smoking.
- Subject must have an intact bladder
- Subject must be scheduled to have a cystoscopy to screen for transitional call bladder cancer due to the finding of hematuria.
- Subject must be able to provide a minimum of 25 mL of urine for study purposes.
- Urine samples must be available prior to cystoscopy, bladder biopsy, and TUR.
- Subjects must be willing to sign an Institutional Review Board approved written informed consent prior to any study related procedures being performed.
Exclusion criteria
- Subject had a history or current diagnosis of any basal or squamous cell cancer.
- Subject had a known diagnosis of any autoimmune disease.
- Subject had known diagnosis of HIV, HCV or HBV
- Subject had disclosed voluntarily history of or current infection with TB or other systemic disease.
- Subject is currently pregnant or lactating.
- Subject had surgery within 30 days prior to enrollment
- Subject has known allergy to benzalkonium chloride.
- Subject participated in an investigational drug or device trial within 30 days prior to enrollment.
Treatment and study plan
Primary outcomes
-
To establish the performance characteristics of the Predictive Biosciences Assay relative to the cystoscopy results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria
Time frame: Initial Visit only
Secondary outcomes
-
To establish the performance characteristics of the PB assay relative to urine cytology results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria.
Time frame: Initial Visit
Sponsors and collaborators
Lead sponsor
Predictive Biosciences
Industry
Registry information
Official study title
Phase 3 Study of Hematuria Evaluation
Important dates
- Study start
- 2009
- Primary completion
- 2010
- Study completion
- 2011
- First posted
- Sep 11, 2009
- Registry last updated
- Jun 8, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.